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Abstract A chimeric cDNA construct encoding the extracel-
lular amino-terminal domain (ECD) of the thyrotropin receptor
fused to the signal for addition of glycosylphosphatidylinositol
from the Thy-1 gene directs efficient expression of the ECD at
the plasma membrane of transfected CHO cells. A cell line
(GT14) expressing over 106 receptors/cell was isolated, which
allows direct detection, by flow cytometry, of autoantibodies
from the majority of patients with Graves’ disease or auto-
immune idiopathic myxedema. Treatment of GT14 cells with a
glycosylphosphatidylinositol-specific phospholipase C (PI-PLC)
releases a soluble 80 kDa molecule which neutralizes the
autoantibodies from Graves patients. Whereas it does not bind
TSH when released from the cells by PI-PLC in free form, the
soluble ECD displays clear TSH binding activity when it is
released as a complex with a monoclonal antibody recognizing a
conformational epitope of the ECD. Our results allow production
of bioactive ECD of the thyrotropin receptor in high yield, with
possible applications in structural analyses.
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1. Introduction
Together with the other glycoprotein hormone receptors,
the thyrotropin receptor (TSHr) displays a bipartite structure,
with a large amino-terminal extracellular domain (ECD) re-
sponsible for high a⁄nity binding of the hormone and a ser-
pentine carboxy-terminal portion, characteristic of the opsin
family of G protein-coupled receptors [1^3]. Attempts to
understand the interplay between both domains in the mech-
anism of activation of the receptor have justi¢ed numerous
studies, mainly involving site-directed mutagenesis (for refer-
ences, see [4^6]). A logical approach to such studies would be
the production of the two portions of the receptor in isolation.
In particular, availability of the amino-terminal domain in
soluble form would constitute an invaluable tool to de¢ne
precisely its interaction with TSH or autoantibodies from pa-
tients with Graves’ disease. Whereas this was achieved rela-
tively easily for the LH/CG receptor [7], production of the
bioactive (i.e. capable of binding TSH) amino-terminal por-
tion of the TSHr has proved a very di⁄cult task.
Most available expression systems have been tried: Esche-
richia coli [7^10], acellular translation [11,12], the baculovirus
system [13^16] and mammalian cells [10,17^21]. Only recently
has it been possible to obtain soluble ECD preparations that
e⁄ciently bind autoantibodies, by making truncated con-
structs in CHO cells [21], or a ECD-CD8 chimera with a
thrombin site engineered at the junction of the chimera
[19,20]. With one notable recent exception [19], preparations
capable of binding TSH are still lacking.
In the present study we have succeeded in expressing high
levels of bioactive ECD of the TSHr at the surface of CHO
cells, via anchoring by a glycosylphosphatidylinositol (GPI)
moiety [22,23]. The ECD can be released from the cell surface
by a GPI-speci¢c phospolipase-C (PI-PLC), in a form capable
of binding Graves’ autoantibodies, but also TSH, provided it
is stabilized by a monoclonal antibody recognizing a confor-
mational epitope of the receptor.
2. Materials and methods
2.1. Reagents
The BA8 and 3G4 monoclonal antibodies recognize a conforma-
tional epitope [24] and a linear epitope (VFFEEQE, residues 355^362,
unpublished) of the ECD, respectively. PI-PLC was purchased from
Boehringer, Mannheim. Iodinated bovine TSH (bTSH) and TRAK
assay reagents were kind gifts from Brahms Diagnostica (Berlin).
2.2. Construction of TSHr ECD with a GPI anchor
A 170 bp fragment encoding the signal peptide for GPI addition at
the C-terminus of mouse Thy-1 cDNA and contained in plasmid
pTM813 [23] was PCR-ampli¢ed using the upstream primer 5P-TT-
AGAATTCAGCTCCAATAAAAGTATCAGTGTGTA-3P and the
downstream primer 5P-ATTGGATCCTCACAGAGAAATGAAGT-
CTAGG-3P. The PCR product was digested with EcoRI and BamHI
and inserted into the prokaryotic vector SK. The resulting construct
was digested with EcoRV and EcoRI, and an oligonucleotide adapter
encoding DIMGYKEF (see Fig. 1) was inserted (upper strand: 5P-
ATCATGGGCTACAAGG-3P ; lower strand: 5P-AATTCCTTG-
TAGCCCATGAT-3P). An EcoRV site was engineered in position
1230 of the ECD of human TSHr. The resulting construct, in SK,
was excised with XhoI/EcoRV and fused upstream of the segment
encoding the signal for GPI addition. The TSHr-ECD construct
with its signal for GPI attachment is illustrated in Fig. 1. This con-
struct was subcloned in pEFIN, a bicistronic vector developed at
Euroscreen (Brussels, Belgium), and transfected in CHO-K1 cells.
Stable cell lines were selected by resistance to geneticin [25].
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2.3. Flow cyto£uorometry with BA8 or 3G4 antibodies or autoimmune
sera
The experiments were performed as described previously [24]. In-
cubation with antibodies was for 30 min at room temperature with
100 Wl PBS-BSA 0.1% containing 10 Wl culture supernatant from BA8
or 3G4 hybridoma, or 10 Wl of autoimmune patient serum.
2.4. Extraction of GPI-anchored TSHr-ECD with Triton X-100
Con£uent cells were detached from the plates with PBS-EDTA/
EGTA, centrifuged at 500Ug for 3 min and washed twice with
PBS. 5U106 cells were resuspended in 100 Wl of 1% (v/v) Triton X-
100 in PBS containing protease inhibitors (Complete, Boehringer,
Mannheim) and incubated on ice for 30 min. The samples were cen-
trifuged at 13 000Ug for 10 min and the supernatants were collected
for Western blotting with the 3G4 antibody [24] (chemiluminescence
kit RPN2108, Amersham Pharmacia Biotech, Gent, Belgium), or
binding experiments.
2.5. Release of TSHr-ECD from its GPI anchor by PI-PLC
For binding with radiolabelled TSH, cells grown in 96-well plates
(2U104 cells/well) were washed twice with DMEM without serum and
incubated for 1, 2 or 3 h at 37‡C with various amounts of PI-PLC in
the same medium containing protease inhibitors (see above). Cells
were washed twice with binding bu¡er and radiolabelled TSH was
added. Binding was performed as described below.
For binding experiments with polyethylene glycol (PEG) precipita-
tion, cells were removed from two 9 cm dishes with PBS-EDTA/
EGTA, washed with PBS and incubated with 0.5 U PI-PLC in
100 Wl of binding bu¡er with protease inhibitors for 1 h at 37‡C. Cells
were centrifuged at 13 000Ug for 10 min and the supernatant stored
at 320‡C.
For FACS analysis, 300 000 cells in 3 cm dishes were washed twice
with DMEM with protease inhibitors, and incubated with 0.5 U PI-
PLC in DMEM, at 37‡C for 1 h. Cells were then washed twice with
PBS and FACS analysis performed as described above.
For deglycosylation and Western blotting, cells from one 9 cm Petri
dish were washed twice with PBS and incubated for 1 h at 37‡C with
PI-PLC (1 U/ml) in DMEM with protease inhibitors. The medium
was removed and concentrated with Ultrafree (NMWL 5000, Milli-
pore) to a ¢nal volume of 500 Wl. Cells were washed twice with PBS,
scraped from the dish and centrifuged at 13 000Ug for 10 min at 4‡C.
The pellet was solubilized for 30 min on ice in 500 Wl of PBS con-
taining 1% Triton X-100. The insoluble material was removed by
centrifugation at 13 000Ug for 15 min.
2.6. Removal of carbohydrates
30 Wl of the concentrated medium containing the material released
from cells by PI-PLC, or 30 Wl of the material solubilized by 1%
Triton X-100 from PI-PLC treated cells were denatured by boiling
for 10 min in SDS 0.5%, L-mercaptoethanol 1%. After centrifugation
(10 min, 13 000Ug), 10 Wl samples of the supernatants were treated
for 16 h at 37‡C with 2 U of N-glycosidase F, or 50 mU endoglyco-
sidase H in a ¢nal volume of 50 Wl containing 1% Triton X-100 and
50 mM phosphate bu¡er pH 7.5, or 50 mM citrate bu¡er pH 5.5.
Control samples were incubated under identical conditions in the
absence of enzymes. After addition of 15 Wl of 5USDS-PAGE loading
bu¡er and boiling for 10 min, 20 Wl samples were loaded on 8%
polyacrylamide gels, and Western blotting was performed as described
above.
2.7. TSH binding to GPI-anchored TSHr-ECD in intact cells
Thyrotropin binding was measured on GT14 or JP19 cells as pre-
viously described with minor modi¢cations [26]. Brie£y 2U104 cells/
well in 96 well plates were incubated with [125I]TSH (30 000 cpm) for
4 h at room temperature in 0.1 ml modi¢ed Hanks’ bu¡er without
NaCl (isotonicity maintained with 280 mM sucrose), supplemented
with 5% BSA. After rapid rinsing with the same bu¡er at 0‡C and
solubilization with 0.2 ml 1 N NaOH, radioactivity was measured in a
gamma counter. All experiments were done in triplicate and results
are expressed as cpm bound.
2.8. Adsorption of TBII activity on GPI-anchored TSHr-ECD released
with PI-PLC
TBII activity in the sera from patients with autoimmune thyroid
diseases was measured with a commercial TRAK assay (Brahms, Ber-
lin), in the presence or absence of TSHr-ECD released from its GPI
anchor on GT14 cells by PI-PLC.
Brie£y, 50 Wl of autoimmune sera were incubated for 20 min at
20‡C with 50 Wl of solubilized porcine thyroid membrane, in the
presence of 10 Wl of soluble TSHr-ECD released from GT14 cells
by PI-PLC (see above). Labeled [125I]bTSH was added and incubation
was for 2 h at 20‡C. 2 ml of the precipitating solution (PEG) was
added, the tubes were centrifuged 15 min at 2500Ug and the radio-
activity in the pellet counted. Results were calculated against the
standard curve provided in the TRAK assay. For some patients
with very high TRAK values (s 405 IU), the same test was performed
after dilution of the sera (see Section 3).
2.9. Binding of radioiodinated TSH to GPI-anchored TSHr-ECD
released by PI-PLC
GT14 or JP02 control cells were detached with PBS-EGTA/EDTA,
and washed twice with PBS. 106 cells were incubated with 500 ng of
native BA8 antibody (or BA8 antibody previously denatured by a
10 min incubation at 100‡C) in 100 Wl of binding bu¡er for 1 h on
ice. Cells were treated with Triton X-100 or PI-PLC as described
above. After centrifugation at 13 000Ug for 10 min, 90 Wl of soluble
material was transferred to a 5 ml tube, 100 Wl of [125I]bTSH
(20 000 cpm) was added and the sample was incubated for 4 h at
4‡C, in the presence or absence of 100 mU/ml cold bTSH. 50 Wl of
bovine Q-globulins (10 mg/ml) were added followed by 2 ml of ice-cold
PEG 4000 15% in NaCl 1 M. After centrifugation for 30 min at
1500Ug, the radioactivity in the pellet was measured.
3. Results and discussion
3.1. A GPI-anchored ECD of the TSHr is e⁄ciently expressed
at the plasma membrane
The 53 amino acid signal peptide for GPI anchor addition
from mouse Thy-1 was fused at position 415 of the TSH
receptor (see Section 2 and Fig. 1). This peptide includes
two putative N-glycosylation sites, respectively before (NKS)
and after (NTS) the site for cleavage and GPI addition (Fig.
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Fig. 1. Schematic representation of the GPI-anchored TSHR-ECD chimeric protein. The C-terminal part of the chimeric Thy-1 TSHr-ECD
construct is shown; fusion is realized after position 415 of the TSHr, with two intervening amino acids (EF) preceding 53 residues of the mouse
Thy-1 molecule responsible for GPI addition. The two potential sites of N-glycosylation (NKS and NTS) introduced with the Thy-1 GPI at-
tachment signal are underlined.
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1). The construct was transfected in CHO cells and one cell
line (GT14) expressing particularly high levels of ECD at the
cell surface was selected by £ow cytometry, using BA8, a
monoclonal antibody recognizing a conformational epitope
of the ECD (Fig. 2A) [24]. The immunoreactive ECD was
e¡ectively anchored by a GPI moiety, since it could be re-
moved from the cells by treatment with PI-PLC (Fig. 2B).
The GPI-anchored ECD at the surface of GT14 cells was
also probed with the monoclonal antibody 3G4 (Fig. 2B,
black bars). This monoclonal recognizes a linear epitope (see
Section 2) present in a ‘connecting’ peptide which has been
shown to be removed from a fraction of holoreceptors ex-
pressed at the surface of transfected cells [27,28]. It is similar
to the 2C11 antibody described previously [29]. The ratio
between the 3G4 and BA8 signals for GT14 and JP19 cells,
expressing the GPI-ECD and holoreceptor, respectively, was
about 2.5-fold higher for GT14 cells (Fig. 2C). This suggests
that the proportion of receptor molecules with the connecting
peptide removed (if any) is lower in GT14 than in JP19 cells.
On Western blots using the 3G4 monoclonal antibody, the
material released from the cells by PI-PLC migrates as a 100
kDa band (Fig. 3, lanes 5 and 7). This material is converted to
a 62 kDa species by treatment with N-glycosidase F (Fig. 3,
lanes 6 versus 5). It is completely resistant to endoglycosidase
H (lanes 8 versus 7), suggesting that it corresponds to a ma-
ture protein with complex carbohydrate chains. A soluble
ECD with a lower apparent molecular weight of 82 kDa
was recently produced from a construct with an engineered
thrombin cleavage site [19]. It is likely that this di¡erence in
size is accounted for by glycosylation of the GPI-ECD at the
level of the ¢rst site for N-glycosylation which is present in the
signal peptide for GPI addition (NKS, see Fig. 1).
Triton X-100 extraction of the material remaining in cells
after PI-PLC treatment releases a major band of 80 kDa, in
addition to residual amounts of 100 kDa material (Fig. 3,
lanes 1 and 3). This 80 kDa species is sensitive to both N-
glycosidase F (lanes 2 versus 1) and endoglycosidase H (lanes
4 versus 3), suggesting that it corresponds to intracellular
precursors of the GPI-ECD with immature high-mannose car-
bohydrates.
It must be stressed that the ECD molecules identi¢ed here
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Fig. 2. Analysis of cell surface expression of GPI-anchored TSHr by
£ow cyto£uorometry. A: Histograms showing binding of the BA8
antibody to a CHO line expressing the GPI-anchored TSHr-ECD
(GT14) or no receptor (JP02). B: CHO cells expressing the GPI-
anchored TSHr-ECD (GT14) or the full-length TSHr (JP19) were
incubated with (black bars) or without (white bars) PI-PLC as de-
scribed in Section 2. Binding of the BA8 antibody was assayed by
£ow cyto£uorometry and quantitated as mean £uorescence. C:
Same as in B except that no PI-PLC was used and that binding was
assayed for BA8 (black bars), 3G4 (white bars) or an irrelevant
antibody (gray bars).
Fig. 3. Analysis of GPI-anchored TSHr-ECD by immunoblotting
with the 3G4 antibody. GT14 cells were treated with PI-PLC (see
Section 2). Lanes 1^4, Triton X-100 extracts from cells after PI-
PLC treatment; lanes 5^8, material released from the cells by PI-
PLC; lanes 1 and 5, overnight control incubation in phosphate
bu¡er; lanes 2 and 6, overnight incubation in phosphate bu¡er con-
taining N-glycosidase F; lanes 3 and 7, overnight control incubation
in citrate bu¡er; lanes 4 and 8, overnight incubation in citrate
bu¡er containing endoglycosidase H.
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all contain the 3G4 epitope, which is included in the peptide
connecting the two subunits of the TSHr in its precursor
[27,28]. As the apparent molecular weights of the molecules
released from the cells by SDS, Triton X-100 or PI-PLC were
the same whether or not the samples were reduced before
electrophoresis (not shown), we conclude that the ECD mol-
ecules identi¢ed here are made of a monomeric polypeptide
chain.
3.2. TSH binds with high a⁄nity to the GPI-anchored ECD at
the surface of GT14 cells
Intact GT14 cells bind [125I]bTSH with an a⁄nity compa-
rable to that of JP19 cells [25] expressing the full-length hol-
oreceptor (Kd, 5.6 vs. 3.5 mIU/ml, for GT14 and JP19 cells,
respectively) (Fig. 4A). The binding was completely lost after
pretreatment of the cells with PI-PLC (Fig. 4B), which was
without e¡ect on the binding to JP19 cells (not shown). Esti-
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Fig. 4. TSH binding to GPI-anchored TSHr-ECD in intact cells. A: CHO lines expressing the GPI-anchored TSHr-ECD (GT14, solid circles)
or full length TSHr (JP19, open circles) were incubated with 30 000 cpm of [125I]bTSH and varying concentrations of cold bTSH. Each point
was tested in triplicate and the results are expressed as bound radioactivity. B: GT14 cells expressing the GPI-anchored TSHr-ECD were
treated for various time periods with increasing concentrations of PI-PLC and binding of [125I]bTSH to the cells was measured (see Section 2).
Fig. 5. Flow cyto£uorometry of autoantibody binding to CHO cells expressing the GPI-anchored TSHr-ECD (GT14, open bars) or no receptor
(JP02, solid bars). Cells were incubated with sera (1:10) from patients with autoimmune hypothyroidism (‘hypo’) or Graves’ disease (‘hyper’).
Fluorescence was analyzed as described in Section 2. Some sera (indicated with asterisks) exhibited elevated £uorescence on the two cell lines.
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mation of the number of TSHr/cell from analysis of the bind-
ing curves [30] gave numbers in excess of 106.
Expression of ECD of the TSHr in a form capable of bind-
ing TSH with high a⁄nity has been unexpectedly di⁄cult. The
present results demonstrate that high a⁄nity binding of TSH
to the TSHr does not require interaction with, or the presence
of the serpentine portion of the receptor. They agree with
recent data showing binding to ECD anchored to the cell
by a CD8 transmembrane segment [19]. This does not exclude
that the extracellular loops of the serpentine portion of the
receptor may interact with the hormone, as suggested by some
site-directed mutagenesis experiments [31,32]. It indicates,
however, that, as for the other glycoprotein hormone recep-
tors, the major high a⁄nity interaction is between the hor-
mone and the ECD.
3.3. The GPI-anchored TSHr-ECD allows direct detection of
autoantibodies by £ow cytometry
Direct detection of the interaction between autoantibodies
and the TSH receptor has been achieved in rare instances, and
only with a handful of potent antisera [33,34]. It was con-
cluded from these observations that TSAbs must be present
in very low concentrations in the serum of patients with
Graves’ disease [33,34]. Incubation of intact GT14 cells with
a panel of sera from patients with Graves’ disease or auto-
immune hypothyroidism yielded clearly positive signals in
£ow cytometry for the majority of them (Fig. 5). The need
for stringent controls in such type of experiments is illustrated
by a series of false positives, giving as strong signals with the
control JP02 cells as with GT14 cells (see e.g. Fig. 5, asterisk).
A rough direct relation was observed between the level of
TBII in the serum and the £uorescence signal (compare results
from serum with TRAKs 100 U/l and 6 100 U/l, Fig. 5).
Also, sera from patients with autoimmune hypothyroidism
tended to give stronger £uorescent signals than those from
Graves patients (‘Hypo’ vs. ‘Hyper’, Fig. 5). This observation
suggests that blocking antibodies have a higher titer than
stimulating antibodies. Whether the positive results obtained
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Fig. 6. Neutralization with soluble TSHr-ECD of autoantibodies to the TSHr present in the serum of patients with autoimmune hypothyroid-
ism or Graves disease. The TRAK assay (Section 2) was modi¢ed by preincubating sera (with TBII levels ranging from 0 to s 405 U/l) with
the soluble material released from GT14 cells by PI-PLC (open bars) or control bu¡er (solid bars). Results are expressed in U/l. Sera 69 and
77 were used after dilution in a further experiment (see Fig. 7).
Fig. 7. Neutralization with soluble TSHr-ECD of autoantibodies to the TSHr present in the serum of patients with autoimmune hypothyroid-
ism (serum 69), or Graves’ disease (serum 77) exhibiting very high TBII levels (s 405 U/l). Sera were diluted in normal human serum and incu-
bated with soluble TSHr-ECD (solid squares) or control bu¡er (open circles) before performing the TRAK assay (see legend to Fig. 6).
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with the GPI-ECD are explained by the higher amounts of
antigens at the surface of GT14 cells, as compared to those
expressing the holoreceptor [33,34], or to a structural pecu-
liarity of the GPI-ECD antigen remains to be determined. The
GPI-TSHr at the surface of GT14 cells constitutes a novel
reagent, with promising characteristics for the development
of new direct assays of autoantibodies against the TSHr.
3.4. The soluble TSHr-ECD released by PI-PLC binds
autoantibodies but not TSH
A batch of 106 GT14 cells was treated with PI-PLC and the
material released from the cells was assayed for its ability to
bind [125I]bTSH by precipitation with PEG. No binding was
detected (see below). This characteristic of the soluble ECD,
severed from the GPI moiety, was exploited to test whether it
would compete for binding of autoantibodies, with the por-
cine TSHr present in the TRAK assay system (see Section 2).
A series of sera with a spectrum of TBII values were tested
(Fig. 6). The soluble ECD competed e⁄ciently with the por-
cine receptor for most of the sera with an intermediate or low
TBII value. With a few exceptions, sera with a very strong
TBII value tended to resist competition. To investigate if the
absence of competition for the strongly positive sera could
re£ect a quantitative problem due to an excess of autoanti-
bodies capable of saturating both the porcine receptor (of the
TRAK) and the GPI-ECD, the same experiments were per-
formed with a selection of such sera, after serial dilution. Fig.
7 illustrates the results obtained with two sera with a partic-
ularly high TBII value (serum 77 and 69 in Fig. 6,
TRAKs 400 U/l). While competition between GPI-ECD
and the porcine TSHr of the TRAK was not observed with
undiluted serum, it was readily detected as soon as the
amounts of immunoglobulins in the assay were reduced.
Together with the £ow cytometry experiments, this indicates
that the GPI-ECD material, be it soluble or anchored in the
plasma membrane, contains a large proportion of the
epitopes recognized by autoantibodies from patients. It also
suggests that the concentration of autoantibodies recog-
nizing the receptor may be relatively high in some of the
samples.
These results agree with observations from many groups
that soluble or solubilized ECD preparations of the TSHr
that are unable to bind TSH display e⁄cient binding of auto-
antibodies [14,16,19,21,35]. In some studies involving trun-
cated versions of the ECD [19,21], the di¡erential recognition
may be due to the absence of a segment contributing to the
surface of interaction with TSH; in others, including the
present one, using complete ECD constructs, it is likely that
misfolding, abnormal glycosylation or partial denaturation of
the ECD was responsible for the lack of TSH binding
[14,16,35].
3.5. When complexed with BA8, the soluble TSHr-ECD
released by PI-PLC binds TSH
The loss of the capability to bind TSH, when the GPI-ECD
is released from the membrane by PI-PLC does not seem to be
due to gross proteolysis : Western blotting indicates that the
material released migrates as a single major band (Fig. 3). The
possibility was explored that this loss of activity was due to an
intrinsic instability of the ECD, when it is severed from the
serpentine domain and moved away from its natural mem-
brane environment. The BA8 monoclonal antibody, which
recognizes a conformational epitope of the human TSHr
and does not interfere with binding of TSH or autoantibodies
[24], was tested as a potential stabilizer of the ECD structure.
GT14 cells were exposed to native or heat-denatured BA8,
under conditions where the intact monoclonal binds e⁄ciently
to the GPI-ECD at the cell surface (see Fig. 2). The cells were
then treated with PI-PLC and the presence of [125I]TSH bind-
ing activity released in the incubation medium was assayed by
precipitation with PEG. A clear TSH binding activity was
released by PI-PLC in the medium from cells pre-exposed to
native BA8 (Fig. 8B). Absence of BA8 (not shown) or prior
heat denaturation of the monoclonal (Fig. 8A) yielded inac-
tive material. Binding of TSH to the ECD from the Triton
X-100 extract was also enhanced by BA8. These results con-
¢rm recent observations [19,27] demonstrating that the ECD
alone is enough for interaction with TSH.
4. Conclusion
Until very recently, constructs encoding the complete ECD
alone did not yield bioactive material capable of binding TSH
with high a⁄nity (see [21] for references). Together, our re-
sults and those of Osuga et al. [19] suggest that the complete
ECD of the TSH receptor requires additional ‘signal’ sequen-
ces to be correctly targeted to the plasma membrane in a
native form. In the holoreceptor, this signaling is probably
carried out by the serpentine portion of the receptor itself.
The ¢rst two transmembrane segments are not e¡ective, as
the correspondingly truncated versions of the receptor remain
trapped intracellularly (our unpublished experiments). It is
likely that the GPI-anchoring peptide (the present study) or
the CD8 transmembrane segment [19] provide adequate sub-
stitutes for this targeting, allowing a signi¢cant proportion of
the ECD molecules to undergo normal glycosylation and ma-
turation, during their journey through the membrane system
of the cell.
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Fig. 8. Binding of [125I]bTSH to the ECD released from GT14 cells by PI-PLC and stabilized by the BA8 antibody. GT14 cells (A and B) or
JP02 cells (C) were exposed to native (B and C) or heat-denatured BA8 (A), under conditions where the intact monoclonal binds e⁄ciently to
the GPI-ECD at the cell surface (see Fig. 2). The cells were treated with PI-PLC (PLC) or Triton X-100 (TX100) and [125I]TSH binding in the
presence (open bars) or absence (solid bars) of an excess of cold bTSH (100 mU/ml) was assayed by precipitation with PEG (see Section 2).
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Another characteristic of the ECD of the TSHr, when it is
separated from its normal environment, seems to be its sus-
ceptibility to partial denaturation. Using a wide diversity of
experimental systems, a series of laboratories succeeded in
making ECD material that is e⁄ciently recognized by auto-
antibodies but fails to bind TSH. Complex formation between
a protein of interest and a natural or arti¢cial ligand recog-
nizing its native structure has been used to stabilize labile
proteins with a view to structure determination by X-ray crys-
tallography [36,37]. Our results with the BA8 monoclonal
antibody indicate that this approach constitutes a promising
means to prepare large amounts of the ECD of the TSHr,
opening the way to a direct determination of its three-dimen-
sional structure.
When the present study was completed, a similar approach
was published by Da Costa and Johnstone [38]. Results are in
good general agreement with ours, but no indication was giv-
en that the soluble ECD could bind TSH.
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